---
title: Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride Camera
nct_id: NCT06828705
overall_status: NOT_YET_RECRUITING
sponsor: Central Hospital, Nancy, France
study_type: OBSERVATIONAL
primary_condition: Neurodegenerative Diseases
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06828705.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06828705"
ct_last_update_post_date: 2025-07-22
last_seen_at: "2026-05-12T07:07:18.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride Camera

**Official Title:** Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride (CZT) Camera (VERITON-CT)

**NCT ID:** [NCT06828705](https://clinicaltrials.gov/study/NCT06828705)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 300
- **Lead Sponsor:** Central Hospital, Nancy, France
- **Conditions:** Neurodegenerative Diseases
- **Start Date:** 2025-07-30
- **Completion Date:** 2025-11-30
- **CT.gov Last Update:** 2025-07-22

## Brief Summary

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

## Detailed Description

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

There are several types of cameras allowing its performance:

* Conventional Anger cameras and,
* CZT (Cadmium-Zinc-Telluride) semiconductor cameras. At the Nancy University Hospital, the nuclear medicine department has a wide-field Cadmium-Zinc-Telluride camera: VERITON-CT (Spectrum Dynamics). The interpretation of this examination is purely visual.

The objectives are therefore to:

* Create the first international database of semi-quantitative values in 3D scintigraphy with Datscan performed with a VERITON-CT camera.
* Compare this database with another database from a conventional Anger camera (Lyon Nuclear Medicine Department) to show its superiority.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 99 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Adult patients who have undergone a Datscan scintigraphy on the VERITON camera in the nuclear medicine department of the Nancy University Hospital and who have an established clinical diagnosis, -Absence of neurodegenerative pathology or Parkinson's disease or Lewy body disease.
* The clinical diagnosis can only be established after two years of clinical follow-up.

Exclusion Criteria:

* Excluded from this research will be the patients opposed to the use of their data, minors, atypical Parkinsonian syndromes,
* patients who died before two years of clinical follow-up,
* patients who had their Datscan examination carried out on a camera other than the VERITON and - patients lost to follow-up.
```

## Interventions

- **datscan scintigraphy** (OTHER) — Semi-quantitative analysis on Datscan imaging scintigraphy

## Primary Outcomes

- **To create the first international database of Datscan by camera VERITON-CT.** _(time frame: One day)_ — Fixation ratio of central gray nuclei of the brain namely, the global striatum, caudate nuclei, putamens

## Secondary Outcomes

- **Compare this database with another database from another type of camera (Lyon nuclear medicine team) to show its superiority.** _(time frame: One day)_

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06828705.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06828705*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*